FLAsH-IV-AML: A phase I/II multi-center study to assess the tolerability and efficacy of the addition of hydroxyurea to salvage treatment with fludarabine, ara-C, idarubicin and venetoclax for adults with relapsed or refractory acute myeloid leukemia
Not yet recruitingCTIS2026-526961-76-00
Karolinska University HospitalAdults (≥ 18 years of age) with relapsed or refractory acute myeloid leukemia (R/R AML)
Target: 26Updated: 2026-07-14